| |
Inhaled β2-Adrenoceptor Agonists
- 作者：Mario Cazzola (1)
Maria G. Matera (2)
Dr Claudio F. Donner (3)
- 刊名：Drugs
- 出版年：2005
- 出版时间：August 2005
- 年：2005
- 卷：65
- 期：12
- 页码：1595-1610
- 全文大小：287KB
- 参考文献：1. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-6
2. Bennett A, Tattersfield AE. Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects. Thorax 1997; 52: 458-4 f="http://dx.doi.org/10.1136/thx.52.5.458">CrossRef
3. Lipworth BJ, McDevitt DG. Inhaled β2-adrenoceptor agonists in asthma: help or hindrance? Br J Clin Pharmacol 1992; 33: 129-8 f="http://dx.doi.org/10.1111/j.1365-2125.1992.tb04014.x">CrossRef
4. Wong CS, Pavord ID, Williams J, et al. Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet 1990; 336: 1396- f="http://dx.doi.org/10.1016/0140-6736(90)93099-B">CrossRef
5. Jouven X, Desnos M, Guerot C, et al. Predicting sudden death in the population: the Paris Prospective Study I. Circulation 1999; 99: 1978-3 f="http://dx.doi.org/10.1161/01.CIR.99.15.1978">CrossRef
6. de Bruyne MC, Hoes AW, Kors JA, et al. QTc dispersion predicts cardiac mortality in the elderly: the Rotterdam Study. Circulation 1998; 97: 467-2 f="http://dx.doi.org/10.1161/01.CIR.97.5.467">CrossRef
7. Manttari M, Oikarinen L, Manninen V, et al. QT dispersion as a risk factor for sudden cardiac death and fatal myocardial infarction in a coronary risk population. Heart 1997; 78: 268-2
8. Copie X, Hnatkova K, Staunton A, et al. Predictive power of increased heart rate versus depressed left ventricular ejection fraction and heart rate variability for risk stratification after myocardial infarction: results of a two-year follow-up study. J Am Coll Cardiol 1996; 27: 270- f="http://dx.doi.org/10.1016/0735-1097(95)00454-8">CrossRef
9. Siegel D, Hulley SB, Black DM, et al. Diuretics, serum and intracellular electrolyte levels, and ventricular arrhythmias in hypertensive men. JAMA 1992; 267: 1083- f="http://dx.doi.org/10.1001/jama.1992.03480080053026">CrossRef
10. Olsson SB. Nature of cardiac arrhythmias and electrolyte disturbances: role of potassium in atrial fibrillation. Acta Med Scand Suppl 1981; 647: 33-
11. Fisch C. Relation of electrolyte disturbances to cardiac arrhythmias. Circulation 1973; 47: 408-9 f="http://dx.doi.org/10.1161/01.CIR.47.2.408">CrossRef
12. Bristow MR. β-Adrenergic receptor blockade in chronic heart failure. Circulation 2000; 101: 558-9 f="http://dx.doi.org/10.1161/01.CIR.101.5.558">CrossRef
13. Brodde OE. β1- and β2-adrenoceptors in the human heart: properties, function and alterations in chronic heart failure. Pharmacol Rev 1991; 43: 203-2
14. Bristow MR, Ginsburg R, Umans V, et al. β1- and β2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective β1-receptor down-regulation in heart failure. Circ Res 1986; 59: 297-09 f="http://dx.doi.org/10.1161/01.RES.59.3.297">CrossRef
15. Xiao RP, Cheng H, Zhou YY, et al. Recent advances in cardiac β2-adrenergic signal transduction. Circ Res 1999; 85: 1092-00 f="http://dx.doi.org/10.1161/01.RES.85.11.1092">CrossRef
16. Rodefeld MD, Beau SL, Schuessler RB, et al. β-adrenergic and muscarinic cholinergic receptor densities in the human sinoatrial node: identification of a high β2-adrenergic receptor density. J Cardiovasc Electrophysiol 1996; 7: 1039-9 f="http://dx.doi.org/10.1111/j.1540-8167.1996.tb00479.x">CrossRef
17. Newton GE, Parker JD. Acute effects of β1-selective and non-selective β-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure. Circulation 1996; 94: 353- f="http://dx.doi.org/10.1161/01.CIR.94.3.353">CrossRef
18. Brodde OE, Michel MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 1999; 51: 651-0
19. Xiao RP, Zhu W, Zheng M, et al. Subtype-specific β-adrenoceptor signaling pathways in the heart and their potential clinical implications. Trends Pharmacol Sci 2004; 25: 358-5 f="http://dx.doi.org/10.1016/j.tips.2004.05.007">CrossRef
20. Clark RB, Knoll BJ, Barber R. Partial agonists and G protein-coupled receptor desensitization. Trends Pharmacol Sci 1999; 20: 279-6 f="http://dx.doi.org/10.1016/S0165-6147(99)01351-6">CrossRef
21. Hanania NA, Sharafkhaneh A, Barber R, et al. β-Agonist intrinsic efficacy: measurement and clinical significance. Am J Respir Crit Care Med 2002; 165: 1353- f="http://dx.doi.org/10.1164/rccm.2109060">CrossRef
22. Qing F, Rahman SU, Rhodes CG, et al. Pulmonary and cardiac β-adrenoceptor density in vivo in asthmatic subjects. Am J Respir Crit Care Med 1997; 55: 1130-
23. Johnson M. Salmeterol. Med Res Rev 1995; 15: 225-7 f="http://dx.doi.org/10.1002/med.2610150303">CrossRef
24. Johnson M, Butchers PR, Coleman RA, et al. The pharmacology of salmeterol. Life Sci 1993; 52: 2131-3 f="http://dx.doi.org/10.1016/0024-3205(93)90728-L">CrossRef
25. Gr?nner?d TA, von Berg A, Schwabe G, et al. Formoterol via Turbuhaler gave better protection than terbutaline against repeated exercise challenge for up to 12 hours in children and adolescents. Respir Med 2000; 94: 661- f="http://dx.doi.org/10.1053/rmed.2000.0789">CrossRef
26. P?nicke K, Heinroth-Hoffmann I, Brodde O-E. Role of β1- and β2-adrenoceptors in hypertrophic and apoptotic effects of noradrenaline and adrenaline in adult rat ventricular cardiomyocytes, Naunyn-Schmiedebergs. Arch Pharmacol 2003; 367: 592- f="http://dx.doi.org/10.1007/s00210-003-0754-z">CrossRef
27. Brodde OE, Leineweber K. Autonomic receptor systems in the failing and aging human heart: similarities and differences. Eur J Pharmacol 2004; 500: 167-6 f="http://dx.doi.org/10.1016/j.ejphar.2004.07.022">CrossRef
28. Sato N, Vatner SF, Shen YT, et al. Effects of cardiac denervation on development of heart failure and catecholamine desensitization. Circulation 1997; 95: 2130-0 f="http://dx.doi.org/10.1161/01.CIR.95.8.2130">CrossRef
29. Lakatta EG, Gerstenblith G, Angell CS, et al. Diminished inotropic response of aged myocardium to catecholamines. Circ Res 1975; 36: 262- f="http://dx.doi.org/10.1161/01.RES.36.2.262">CrossRef
30. Fleg JL, Tzankoff SP, Lakatta EG. Age-related augmentation of plasma catecholamines during dynamic exercise in healthy males. J Appl Physiol 1985; 59: 1033-
31. White M, Roden R, Minobe W, et al. Age-related changes in β-adrenergic neuroeffector systems in the human heart. Circulation 1994; 90: 1225-8 f="http://dx.doi.org/10.1161/01.CIR.90.3.1225">CrossRef
32. Xiao RP, Tomhave ED, Wang DJ, et al. Age-associated reductions in cardiac β1- and β2-adrenergic responses without changes in inhibitory G proteins or receptor kinases. J Clin Invest 1998; 101: 1273-2 f="http://dx.doi.org/10.1172/JCI1335">CrossRef
33. Maesen FPV, Costongs R, Smeets JJ, et al. The effect of maximal doses of formoterol and salbutamol from a metered dose inhaler on pulse rates, ECG, and serum potassium concentrations. Chest 1991; 99: 1367-3 f="http://dx.doi.org/10.1378/chest.99.6.1367">CrossRef
34. Lemaitre RN, Siscovick DS, Psaty BM, et al. Inhaled β2 adrenergic receptor agonists and primary cardiac arrest. Am J Med 2002; 113: 711- f="http://dx.doi.org/10.1016/S0002-9343(02)01384-0">CrossRef
35. Au D, Lemaitre R, Curtis J, et al. The risk of myocardial infarction associated with inhaled β-adrenoceptor agonists. Am J Respir Crit Care Med 2000; 161: 827-0
36. Coughlin SS, Metayer C, McCarthy EP, et al. Respiratory illness, β-agonists, and risk of idiopathic dilated cardiomyopathy: the Washington, DC, Dilated Cardiomyopathy Study. Am J Epidemiol 1995; 142: 395-03
37. Martin R, Dunn N, Freemantle S, et al. Risk of non-fatal cardiac failure and ischaemic heart disease with long acting β2-agonists. Thorax 1998; 53: 558-2 f="http://dx.doi.org/10.1136/thx.53.7.558">CrossRef
38. Newhouse MT, Chapman KR, McCallum AL, et al. Cardiovascular safety of high doses of inhaled fenoterol and albuterol in acute severe asthma. Chest 1996; 110: 595-03 f="http://dx.doi.org/10.1378/chest.110.3.595">CrossRef
39. Palmqvist M, Ibsen T, Mellen A, et al. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 1999; 160: 244-
40. Jartti T, Kaila T, Tahvanainen K, et al. The acute effects of inhaled salbutamol on the beat-to-beat variability of heart rate and blood pressure assessed by spectral analysis. Br J Clin Pharmacol 1997; 43: 421- f="http://dx.doi.org/10.1046/j.1365-2125.1997.00565.x">CrossRef
41. Kaya D, Barutcu I, Esen AM, et al. Comparison of the effects of ipratropium bromide and salbutamol on autonomie heart rate control. Europace 2004; 6: 602- f="http://dx.doi.org/10.1016/j.eupc.2004.07.010">CrossRef
42. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of β-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004; 125: 2309-1 f="http://dx.doi.org/10.1378/chest.125.6.2309">CrossRef
43. Sears MR. Adverse effects of β-agonists. J Allergy Clin Immunol 2002; 110 (6 Suppl.): S322- f="http://dx.doi.org/10.1067/mai.2002.129966">CrossRef
44. Bennett JA, Smyth ET, Pavord ID, et al. Systemic effects of salbutamol and salmeterol in patients with asthma. Thorax 1994; 49: 771- f="http://dx.doi.org/10.1136/thx.49.8.771">CrossRef
45. Braden GL, Germain MJ, Mulhern JG, et al. Hemodynamic, cardiac, and electrolyte effects of low-dose aerosolized terbutaline sulfate in asthmatic patients. Chest 1998; 114: 380- f="http://dx.doi.org/10.1378/chest.114.2.380">CrossRef
46. Braun SR, Levy SF. Comparison of ipratropium bromide and albuterol in chronic obstructive pulmonary disease: a three-center study. Am J Med 1991; 91: 28S-32S f="http://dx.doi.org/10.1016/0002-9343(91)90259-Z">CrossRef
47. Buch J, Bundgaard A. Cardiovascular effects of intramuscular or inhaled terbutaline in asthmatics. Acta Pharmacol Toxicol (Copenh) 1984; 54: 183- f="http://dx.doi.org/10.1111/j.1600-0773.1984.tb01915.x">CrossRef
48. Burgess C, Ayson M, Rajasingham S, et al. The extrapulmonary effects of increasing doses of formoterol in patients with asthma. Eur J Clin Pharmacol 1998; 54: 141- f="http://dx.doi.org/10.1007/s002280050435">CrossRef
49. Burggraaf J, Westendorp RGJ, in’t Veen JCCM, et al. Cardiovascular side effects of inhaled salbutamol in hypoxic asthmatic patients. Thorax 2001; 56: 567- f="http://dx.doi.org/10.1136/thorax.56.7.567">CrossRef
50. Chan CK, Loke J, Snyder PE, et al. Oral terbutaline augments cardiac performance in chronic obstructive pulmonary disease. Am J Med Sci 1988; 296: 33- f="http://dx.doi.org/10.1097/00000441-198807000-00007">CrossRef
51. Marlin GE, Bush DE, Berend N. Comparison of ipratropium bromide and fenoterol in asthma and chronic bronchitis. Br J Clin Pharmacol 1978; 6: 547- f="http://dx.doi.org/10.1111/j.1365-2125.1978.tb00885.x">CrossRef
52. Vathenen AS, Britton JR, Ebden P, et al. High-dose inhaled albuterol in severe chronic airflow limitation. Am Rev Respir Dis 1988; 138: 850- f="http://dx.doi.org/10.1164/ajrccm/138.4.850">CrossRef
53. Riding WD, Dinda P, Chatterjee SS. The bronchodilator and cardiac effects of five pressure-packed aerosols in asthma. Br J Dis Chest 1970; 64: 37-5 f="http://dx.doi.org/10.1016/S0007-0971(70)80047-X">CrossRef
54. Bremner P, Woodman K, Burgess C, et al. A comparison of the cardiovascular and metabolic effects of formoterol, salbutamol and fenoterol. Eur Respir J 1993; 6: 204-0
55. Bremner P, Burgess C, Beasley R, et al. Nebulized fenoterol causes greater cardiovascular and hypokalaemic effects than equivalent bronchodilator doses of salbutamol in asthmatics. Respir Med 1992; 86: 419-3 f="http://dx.doi.org/10.1016/S0954-6111(06)80009-0">CrossRef
56. Tandon MK. Cardiopulmonary effects of fenoterol and salbutamol aerosols. Chest 1980; 77: 429-1 f="http://dx.doi.org/10.1378/chest.77.3.429">CrossRef
57. Gray BJ, Frame MH, Costello JF. A comparative double-blind study of the bronchodilator effects and side effects of inhaled fenoterol and terbutaline administered in equipotent doses. Br J Dis Chest 1982; 76: 341-0 f="http://dx.doi.org/10.1016/0007-0971(82)90068-7">CrossRef
58. Crane J, Burgess C, Beasley R. Cardiovascular and hypokalaemic effects of inhaled salbutamol, fenoterol, and isoprenaline. Thorax 1989; 44: 136-0 f="http://dx.doi.org/10.1136/thx.44.2.136">CrossRef
59. Lipworth BJ, McDevitt DG. β-Adrenoceptor responses to inhaled salbutamol in normal subjects. Eur J Clin Pharmacol 1989; 36: 239-5 f="http://dx.doi.org/10.1007/BF00558154">CrossRef
60. Lipworth BJ, Struthers AD, McDevitt DG. Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics. Am Rev Respir Dis 1989; 140: 586-2
61. Lipworth BJ, Clark RA, Dhillon DP, et al. β-Adrenoceptor responses to high doses of inhaled salbutamol in patients with bronchial asthma. Br J Clin Pharmacol 1988; 26: 527-3 f="http://dx.doi.org/10.1111/j.1365-2125.1988.tb05292.x">CrossRef
62. Paterson JW, Connolly ME, Davies DS, et al. Isoprenaline resistance and the use of pressurised aerosols in asthma. Lancet 1968; II: 426- f="http://dx.doi.org/10.1016/S0140-6736(68)90467-4">CrossRef
63. Lipworth BJ, Clark RA, Dhillon DP, et al. Comparison of the effects of prolonged treatment with low and high doses of inhaled terbutaline on β-adrenoceptor responsiveness in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1990; 142: 338-2
64. Nemec J, Hejlik JB, Shen WK, et al. Catecholamine-induced T-wave lability in congenital long QT syndrome: a novel phenomenon associated with syncope and cardiac arrest. Mayo Clin Proc 2003; 78: 40-0 f="http://dx.doi.org/10.4065/78.1.40">CrossRef
65. Chao CL, Chen WJ, Chen MF, et al. Torsade de pointes in a patient using usual dose of beta agonist therapy. Int J Cardiol 1996; 57: 295- f="http://dx.doi.org/10.1016/S0167-5273(96)02831-8">CrossRef
66. Lipworth B. Revisiting interactions between hypoxaemia and β2-agonists in asthma. Thorax 2001; 56: 506- f="http://dx.doi.org/10.1136/thorax.56.7.506">CrossRef
67. Finn AF, Thompson CM, Banov CH, et al. β2-Agonist induced ventricular dysrhythmias secondary to hyperexcitable conduction system in the absence of a long QT syndrome. Ann Allergy Asthma Immunol 1997; 78: 230- f="http://dx.doi.org/10.1016/S1081-1206(10)63393-5">CrossRef
68. Kiely DG, Cargill RI, Grove A, et al. Abnormal myocardial repolarisation in response to hypoxaemia and fenoterol. Thorax 1995; 50: 1062- f="http://dx.doi.org/10.1136/thx.50.10.1062">CrossRef
69. Jackson CM, Lipworth B. Benefit-risk assessment of long-acting β2-agonists in asthma. Drug Saf 2004; 27(4): 243-0 f="http://dx.doi.org/10.2165/00002018-200427040-00003">CrossRef
70. Cazzola M, Donner CF. Long-acting β2 agonists in the management of stable chronic obstructive pulmonary disease. Drugs 2000; 60(2): 307-0 f="http://dx.doi.org/10.2165/00003495-200060020-00005">CrossRef
71. Ostrom NK. Tolerability of short-term, high-dose formoterol in healthy volunteers and patients with asthma. Clin Ther 2003; 25: 2635-6 f="http://dx.doi.org/10.1016/S0149-2918(03)80325-9">CrossRef
72. Lecaillon JB, Kaiser G, Palmisano M, et al. Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer. Eur J Clin Pharmacol 1999; 55: 131- f="http://dx.doi.org/10.1007/s002280050607">CrossRef
73. Guhan AR, Cooper S, Oborne J, et al. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax 2000; 55: 650- f="http://dx.doi.org/10.1136/thorax.55.8.650">CrossRef
74. Kemp JP, Bierman CW, Cocchetto DM. Dose-response study of inhaled salmeterol in asthmatic patients with 24-hour spirometry and Holter monitoring. Ann Allergy 1993; 70: 316-2
75. Tunaoglu FS, Turktas I, Olgunturk R, et al. Cardiac side effects of long acting β-2 agonist salmeterol in asthmatic children. Pediatr Int 1999; 41: 28-1 f="http://dx.doi.org/10.1046/j.1442-200x.1999.01009.x">CrossRef
76. Tranfa CME, Pelaia G, Grembiale RD, et al. Short-term cardiovascular effects of salmeterol. Chest 1998; 113: 1272- f="http://dx.doi.org/10.1378/chest.113.5.1272">CrossRef
77. Chervinsky P, Goldberg P, Galant S, et al. Long-term cardiovascular safety of salmeterol powder pharmacotherapy in adolescent and adult patients with chronic persistent asthma. Chest 1999; 115: 642- f="http://dx.doi.org/10.1378/chest.115.3.642">CrossRef
78. Maesen FP, Costongs R, Smeets SJ, et al. Formoterol as dry powder inhalation: a dose finding study in comparison with formoterol metered dose inhaler and placebo. Chest 1992; 101: 1376-1 f="http://dx.doi.org/10.1378/chest.101.5.1376">CrossRef
79. Totterman KJ, Huhti L, Sutinen E, et al. Tolerability to high doses of formoterol and terbutaline via Turbuhaler for 3 days in stable asthmatic patients. Eur Respir J 1998; 12(3): 573- f="http://dx.doi.org/10.1183/09031936.98.12030573">CrossRef
80. Lanes SF, Lanza LL, Wentworth III CE. Risk of emergency care, hospitalization, and ICU stays for acute asthma among recipients of salmeterol. Am J Respir Crit Care Med 1998; 158: 857-1
81. Malolepszy J, B?sz?rményi Nagy G, Selroos O, et al. Safety of formoterol Turbuhaler at cumulative dose of 90 μg in patients with acute bronchial obstruction. Eur Respir J 2001; 18: 928-4 f="http://dx.doi.org/10.1183/09031936.01.00251901">CrossRef
82. Therapeutic Products Directorate: TPD-Web [online]. Available from URL: http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/serevent_prof_e.html [Accessed 2005 Feb 20]
83. Shih HT, Webb CR, Conway WA, et al. Frequency and significance of cardiac arrhythmias in chronic obstructive lung disease. Chest 1998; 94: 44- f="http://dx.doi.org/10.1378/chest.94.1.44">CrossRef
84. Goldkorn A, Diotto P, Burgess C, et al. The pulmonary and extra-pulmonary effects of high-dose formoterol in COPD: a comparison with salbutamol. Respirology 2004; 9: 102- f="http://dx.doi.org/10.1111/j.1440-1843.2003.00525.x">CrossRef
85. Ferguson GT, Funck-Brentano C, Fischer T, et al. Cardiovascular safety of salmeterol in COPD. Chest 2003; 123: 1817-4 f="http://dx.doi.org/10.1378/chest.123.6.1817">CrossRef
86. Cazzola M, Imperatore F, Salzillo A, et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with pre-existing cardiac arrhythmias and hypoxemia. Chest 1998; 114: 411- f="http://dx.doi.org/10.1378/chest.114.2.411">CrossRef
87. Cazzola M, D’Amato M, Califano C, et al. Formoterol as dry powder oral inhalation in comparison with salbutamol metered dose inhaler in acute exacerbations of chronic obstructive pulmonary disease. Clin Ther 2002; 24: 595-04 f="http://dx.doi.org/10.1016/S0149-2918(02)85135-9">CrossRef
88. Cazzola M, Califano C, Di Perna F, et al. Acute effects of higher than customary doses of salmeterol and salbutamol in patients with acute exacerbation of COPD. Respir Med 2002; 96: 790- f="http://dx.doi.org/10.1053/rmed.2002.1353">CrossRef
89. Cazzola M, Matera MG, D’Amato M, et al. Long-acting β2 agonists in the treatment of acute exacerbations of COPD. Clin Drug Invest 2002; 22: 369-6 f="http://dx.doi.org/10.2165/00044011-200222060-00004">CrossRef
90. Cazzola M, Santus P, Matera MG, et al. A single high dose of fomoterol is as effective as the same dose administered in a cumulative manner in patients with acute exacerbation of COPD. Respir Med 2003; 97: 458-2 f="http://dx.doi.org/10.1053/rmed.2002.1456">CrossRef
91. Meier CR, Jick SS, Derby LE, et al. Acute respiratory-tract infections and risk of first-time acute myocardial infarction. Lancet 1998; 351: 1467-1 f="http://dx.doi.org/10.1016/S0140-6736(97)11084-4">CrossRef
92. Au DH, Curtis JR, Every NR, et al. Association between inhaled β-agonists and the risk of unstable angina and myocardial infarction. Chest 2002; 121: 846-1 f="http://dx.doi.org/10.1378/chest.121.3.846">CrossRef
93. Willich SN, Linderer T, Wegscheider K, et al. Increased morning incidence of myocardial infarction in the ISAM study: absence with prior beta-adrenergic blockade. ISAM Study Group. Circulation 1989; 80: 853-
94. Tanaka S, Momose Y, Tsutsui M, et al. Quantitative estimation of myocardial fibrosis based on receptor occupancy for β2-adrenergic receptor agonists in rats. J Toxicol Sci 2004; 29: 179-6 f="http://dx.doi.org/10.2131/jts.29.179">CrossRef
95. Mason DA, Moore JD, Green SA, et al. A gain-of-function polymorphism in a G-protein coupling domain of the human β1-adrenergic receptor. J Biol Chem 1999; 274: 12670- f="http://dx.doi.org/10.1074/jbc.274.18.12670">CrossRef
96. Iwai C, Akita H, Kanazawa K, et al. Arg389Gly polymorphism of the human β1-adrenergic receptor in patients with nonfatal acute myocardial infarction. Am Heart J 2003; 146: 106- f="http://dx.doi.org/10.1016/S0002-8703(03)00110-8">CrossRef
97. Rossinen J, Partanen J, Stenius-Aarniala B, et al. Salbutamol inhalation has no effect on myocardial ischaemia, arrhythmias and heart-rate variability in patients with coronary artery disease plus asthma or chronic obstructive pulmonary disease. J Intern Med 1998; 243: 361- f="http://dx.doi.org/10.1046/j.1365-2796.1998.00291.x">CrossRef
98. Suissa S, Assimes T, Ernst P. Inhaled short acting β agonist use in COPD and the risk of acute myocardial infarction. Thorax 2003; 58: 43- f="http://dx.doi.org/10.1136/thorax.58.1.43">CrossRef
99. Hole DJ, Watt GCM, Davey-Smith G, et al. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 1996; 313: 711- f="http://dx.doi.org/10.1136/bmj.313.7059.711">CrossRef
100. Au DH, Udris EM, Curtis JR, et al. Association between chronic heart failure and inhaled β-2-adrenoceptor agonists. Am Heart J 2004; 148: 915-0 f="http://dx.doi.org/10.1016/j.ahj.2004.03.048">CrossRef
101. Sengstock DM, Obeidat O, Pasnoori V, et al. Asthma, β-agonists, and development of congestive heart failure: results of the ABCHF study. J Card Fail 2002; 8: 232- f="http://dx.doi.org/10.1054/jcaf.2002.127771">CrossRef
102. Brodde OE. β-Adrenoceptors in cardiac disease. Pharmacol Ther 1993; 60: 405-0 f="http://dx.doi.org/10.1016/0163-7258(93)90030-H">CrossRef
103. Bohm M. Alterations of β-adrenoceptor-G-protein-regulated adenylylcyclase in heart failure. Mol Cell Biochem 1995; 147: 147-0 f="http://dx.doi.org/10.1007/BF00944795">CrossRef
104. Poller U, Fuchs B, Gorf A, et al. Terbutaline-induced desensitization of human cardiac β2-adrenoceptor-mediated positive inotropic effects: attenuation by ketotifen. Cardiovasc Res 1998; 40: 211-2 f="http://dx.doi.org/10.1016/S0008-6363(98)00101-1">CrossRef
105. Schafers RF, Adler S, Daul A, et al. Positive inotropic effects of the β2-adrenoceptor agonist terbutaline in the human heart: effects of long-term β1-adrenoceptor antagonist treatment. J Am Coll Cardiol 1994; 23: 1224-3 f="http://dx.doi.org/10.1016/0735-1097(94)90615-7">CrossRef
106. Liggett SB, Wagoner LE, Craft LL, et al. The Ile164 β2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest 1998; 102: 1534- f="http://dx.doi.org/10.1172/JCI4059">CrossRef
107. Brode OE, Buscher R, Tellkamp R, et al. Blunted cardiac responses to receptor activation in subjects with Thr164Ile β2-adrenoceptors. Circulation 2001; 103: 1048-0 f="http://dx.doi.org/10.1161/01.CIR.103.8.1048">CrossRef
108. Wagoner LE, Craft LL, Singh B, et al. Polymorphisms of the β2-adrenergic receptor determine exercise capacity in patients with heart failure. Circ Res 2000; 86: 834-0 f="http://dx.doi.org/10.1161/01.RES.86.8.834">CrossRef
109. Mahon NG, McKenna WJ. Genes and acquired disease: β-adrenoceptor polymorphisms and heart failure. Eur Heart J 2000; 21: 1810- f="http://dx.doi.org/10.1053/euhj.2000.2193">CrossRef
110. Murray DR, Prabhu SD, Chandrasekar B. Chronic β-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation 2000; 101: 2338-1 f="http://dx.doi.org/10.1161/01.CIR.101.20.2338">CrossRef
111. Pagani FD, Baker LS, Hsi C, et al. Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-α in conscious dogs. J Clin Invest 1992; 90: 389-8 f="http://dx.doi.org/10.1172/JCI115873">CrossRef
112. Yokoyama T, Vaca L, Rossen RD, et al. Cellular basis of the negative inotropic effects of tumor necrosis factor-α in the adult mammalian heart. J Clin Invest 1993; 92: 2302-2 f="http://dx.doi.org/10.1172/JCI116834">CrossRef
113. Gulick T, Chung MK, Pieper SJ, et al. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte β-adrenergic responsiveness. Proc Natl Acad Sci U S A 1989; 86: 6753- f="http://dx.doi.org/10.1073/pnas.86.17.6753">CrossRef
114. Ng TM, Munger MA, Lombardi WL, et al. Chronically inhaled salmeterol improves pulmonary function in heart failure. J Cardiovasc Pharmacol 2002; 40: 140- f="http://dx.doi.org/10.1097/00005344-200207000-00017">CrossRef
115. Chapman KR, D’Urzo AD, Druck MN, et al. Cardiovascular response to acute airway obstruction and hypoxia. Am Rev Respir Dis 1989; 140: 1222- f="http://dx.doi.org/10.1164/ajrccm/140.5.1222">CrossRef
116. Zimmer G, Dahinten A, Fitzner A, et al. β-Agonistic bronchodilators: comparison of dose/response in working rat hearts. Chest 2000; 117: 519-9 f="http://dx.doi.org/10.1378/chest.117.2.519">CrossRef
117. De Bruin ML, Hoes AW, Leufkens HG. QTc-prolonging drugs and hospitalizations for cardiac arrhythmias. Am J Cardiol 2003; 91: 59-2 f="http://dx.doi.org/10.1016/S0002-9149(02)02998-3">CrossRef
118. Sakamaki F, Satoh T, Nagaya N, et al. Abnormality of left ventricular sympathetic nervous function assessed by 123I-metaiodobenzylguanidine imaging in patients with COPD. Chest 1999; 116: 1575-1 f="http://dx.doi.org/10.1378/chest.116.6.1575">CrossRef
119. MacNee W. Pulmonary circulation, cardiac function and fluid balance. In: Calverley P, Pride N, editors. Chronic obstructive pulmonary diseases.London: Chapman & Hall, 1995: 243-1
120. Mador MJ, Tohin MJ. Acute respiratory failure. In: Calverley P, Pride N, editors. Chronic obstructive pulmonary diseases. London: Chapman & Hall, 1995: 461-5
121. Stewart AG, Waterhouse JC, Howard P. The QTc interval, autonomie neuropathy and mortality in hypoxemic COPD. Respir Med 1995; 89: 79-4 f="http://dx.doi.org/10.1016/0954-6111(95)90188-4">CrossRef
122. Shah L, Wilson AJ, Gibson PG, et al. Long acting β-agonists versus theophylline for maintenance treatment of asthma. Cochrane Database Syst Rev 2003; (3): CD001281
- 作者单位：Mario Cazzola (1)
Maria G. Matera (2)
Dr Claudio F. Donner (3)
1. Department of Respiratory Medicine, Cardarelli Hospital, Unit of Pneumology and Allergology, Naples, Italy
2. Unit of Pharmacology, Department of Experimental Medicine, Second University of Naples, Naples, Italy
3. Division of Pulmonary Disease, Salvatore Maugeri Foundation IRCCS, Scientific Institute of Veruno, Via per Revislate, Veruno, 13, Italy
文摘
Although large surveys have documented the favourable safety profile of β2-adrenoceptor agonists (β2-agonists) and, above all, that of the long-acting agents, the presence in the literature of reports of adverse cardiovascular events in patients with obstructive airway disease must induce physicians to consider this eventuality. The coexistence of β1- and β2-adrenoceptors in the heart clearly indicates that β2-agonists do have some effect on the heart, even when they are highly selective. It should also be taken into account that the β2-agonists utilised in clinical practice have differing selectivities and potencies. β2-agonist use has, in effect, been associated with an increased risk of myocardial infarction, congestive heart failure, cardiac arrest and sudden cardiac death. Moreover, patients who have either asthma or chronic obstructive pulmonary disease may be at increased risk of cardiovascular complications because these diseases amplify the impact of these agents on the heart and, unfortunately, are a confounding factor when the impact of β2-agonists on the heart is evaluated. Whatever the case may be, this effect is of particular concern for those patients with underlying cardiac conditions. Therefore, β2-agonists must always be used with caution in patients with cardiopathies because these agents may precipitate the concomitant cardiac disease.
| |
NGLC 2004-2010.National Geological Library of China All Rights Reserved.
Add:29 Xueyuan Rd,Haidian District,Beijing,PRC. Mail Add: 8324 mailbox 100083
For exchange or info please contact us via email.
| |
